Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00391534
Status:
TERMINATED
Last Update Posted:
2010-04-15
First Post:
2006-10-23
Brief Title:
EXTENT EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy
Sponsor:
Desitin Arzneimittel GmbH
Organization:
Desitin Arzneimittel GmbH
Study Overview
Official Title:
Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine OXC MR vs an Immediate Release Oxcarbazepine OXC IR Product in Patients With Partial Epilepsy
Status:
TERMINATED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Low recruitment rate
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation The study medication will be used as a treatment against partial epilepsy
Detailed Description:
This is a multi-centre randomized open-label flexible-titration controlled parallel-group study to investigate the safety and efficacy of a novel modified release formulation of oxcarbazepine OXC MR compared to an immediate release oxcarbazepine OXC IR product in patients with partial epilepsy Adult patients of both gender aged at least 18 years with refractory partial epilepsy with or without secondary generalisation receiving a stable background treatment with daily dosages of exactly 900 or 1200 or 1500 mg Oxcarbazepine will be enrolled Concomitant medication consisting of maximal 2 additional AEDs vagus nerve stimulator included is allowed and must be kept stable throughout the study Patients who agree to participate will first sign and date the informed consent and undergo an evaluation at screening visit to determine eligibility Those patients who qualify will be enrolled in the study assigned a patient ID and will enter the 4-week baseline period Each patient will receive a seizure diary to record the number of seizures during the baseline period For Visit 1 the patient will return to the clinic and complete all baseline procedures Patients who have met the entry criteria will be randomised The two treatment groups consist of 50 patients each one group to be treated with OXC MR bid and the other to be treated with OXC IR bid in a 11 randomization Following assignment to one of both treatment groups the patient will enter the dose-titration phase From Visit 1 Study Day 1 a total daily dose of 1200 mg 1500 mg 1800 mg oxcarbazepine will be given to the randomised patients From Day 6 the dosage will be titrated to a maximum total daily dose of 2700 mg in steps of 300 mg every 6th day Patients who experienced intolerable adverse events could reduce their daily dose by 150 mg on the 2nd day of up-titration for the remainder of the treatment period In case the reduced dosage will also not be tolerated in a second step the dosage can be reduced by further 150 mg OXC The maximal tolerated dose achieved on up-titration will be maintained up to the final visit Study Day 26
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2006-003834-14 | None | None | None |